| Literature DB >> 35883187 |
Miriam Hattle1, Danielle L Burke2, Thomas Trikalinos3, Christopher H Schmid3, Yong Chen4, Dan Jackson5, Richard D Riley2.
Abstract
OBJECTIVES: Multivariate meta-analysis allows the joint synthesis of multiple outcomes accounting for their correlation. This enables borrowing of strength (BoS) across outcomes, which may lead to greater efficiency and even different conclusions compared to separate univariate meta-analyses. However, multivariate meta-analysis is complex to apply, so guidance is needed to flag (in advance of analysis) when the approach is most useful. STUDY DESIGN ANDEntities:
Keywords: Borrowing of strength; IPD meta-analysis; Meta-analysis; Multivariate meta-analysis
Mesh:
Year: 2022 PMID: 35883187 PMCID: PMC9316363 DOI: 10.1186/s13643-022-01999-0
Source DB: PubMed Journal: Syst Rev ISSN: 2046-4053
Fig. 1Comparison of the univariate and bivariate meta-analysis results on the log odds ratio scale for outcome 1 from the 43 reviews examined by Trikalinos et al., ordered by the magnitude of the BoS statistic
Fig. 2Comparison of the univariate and bivariate meta-analysis results on the log odds ratio scale for outcome 2 for the 43 meta-analyses examined by Trikalinos et al., ordered by the magnitude of the BoS statistic
Unadjusted association of seven meta-analysis characteristics and the magnitude of BoS in a bivariate meta-analysis of two binary outcomes
| Characteristic | Unadjusted effect of characteristics on BoS | ||
|---|---|---|---|
| Coefficient | 95% CI | ||
| Number of studies | 0.19 | <0.001 | 0.09 to 0.29 |
| Number of studies with outcome of interest | 0.17 | 0.013 | 0.04 to 0.31 |
| Number of studies with both outcomes | 0.36 | 0.001 | 0.15 to 0.57 |
| Percentage of studies missing either outcome | 0.49 | <0.001 | 0.24 to 0.74 |
| Percentage of studies missing the outcome corresponding to the BoS value | 0.52 | <0.001 | 0.38 to 0.67 |
| Average absolute within-study correlation | 28.36 | <0.001 | 14.37 to 42.35 |
| Largest absolute within-study correlation | 29.08 | <0.001 | 16.30 to 41.85 |
Adjusted association of seven meta-analysis characteristics and the magnitude of BoS in a bivariate meta-analysis
| Characteristic | Adjusted effect of characteristic on | Adjusted effect of characteristic on | Final model after applying global shrinkage factor of 0.96 |
|---|---|---|---|
| Coefficient (95% CI) | Coefficient (95% CI) | Coefficient | |
| Number of studies | 0.70 (0.13 to 1.27) | 0.65 (0.19 to 1.12) | 0.630 |
| Number of studies with outcome of interest | −0.69 (−1.39 to 0.01) | −0.79 (−1.38 to −0.19) | −0.755 |
| Number of studies with both outcomes | −0.23 (−1.20 to 0.74) | ||
| Percentage of studies missing either outcome | −0.12 (−0.53 to 0.28) | ||
| Percentage of studies missing the outcome corresponding to the BoS value | 0.35 (0.09 to 0.61) | 0.29 (0.10 to 0.48) | 0.282 |
| Average absolute within-study correlation | −9.98 (−33.15 to 13.19) | ||
| Largest absolute within-study correlation | 35.23 (12.49 to 57.98) | 26.59 (16.53 to 36.65) | 25.581 |
| Intercept | −13.90 (−23.22 to −4.58) | −14.05 (−22.85 to −5.26) | −13.020 |
Fig. 3Scatter plot of the observed BoS versus the predicted BoS from the multivariable model after backwards selection (before and after shrinkage)
True and predicted BoS values for two Cochrane reviews, alongside their multivariate and univariate meta-analysis results
| Review (total number of studies) | Outcome | Number of studies with the outcome | Predicted | Observed | Bivariate common-effect meta-analysis | Univariate common-effect meta-analysis for each outcome separately | ||
|---|---|---|---|---|---|---|---|---|
| Summary odds ratio (95% CI) | Standard error of log odds ratio | Summary odds ratio (95% CI) | Standard error of log odds ratio | |||||
| Buzzetti et al. [ | 1: Mortality at 30 days | 9 | 20.1% | 47.7% | 0.89 (0.69 to 1.15) | 0.13 | 0.69 (0.48 to 0.98) | 0.18 |
| 2: Mortality at maximal follow-up | 12 | 10.8% | 3.2% | 0.89 (0.69 to 1.14) | 0.13 | 0.91 (0.70 to 1.17) | 0.13 | |
| Feinberg et al. [ | 1: All-cause mortality at end of intervention | 11 | 21.0% | 32.8% | 0.97 (0.81 to 1.16) | 0.09 | 0.97 (0.78 to 1.20) | 0.11 |
| 2: All-cause mortality at maximum follow-up | 15 | 10.4% | 0.2% | 0.96 (0.82 to 1.12) | 0.08 | 0.96 (0.82 to 1.13) | 0.08 | |